14,15-epoxy-5,8,11-eicosatrienoic acid has been researched along with 17,18-epoxy-5,8,11,14-eicosatetraenoic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albadine, R; Echavé, V; Morin, C; Rousseau, E; Sirois, M | 1 |
1 other study(ies) available for 14,15-epoxy-5,8,11-eicosatrienoic acid and 17,18-epoxy-5,8,11,14-eicosatetraenoic acid
| Article | Year |
|---|---|
17,18-epoxyeicosatetraenoic acid targets PPARγ and p38 mitogen-activated protein kinase to mediate its anti-inflammatory effects in the lung: role of soluble epoxide hydrolase.
Topics: 8,11,14-Eicosatrienoic Acid; Anti-Inflammatory Agents; Arachidonic Acids; Bronchi; Calcium; Cyclooxygenase 2; Epoxide Hydrolases; Humans; Intracellular Signaling Peptides and Proteins; Lung; Models, Biological; Muscle Proteins; Myosin-Light-Chain Phosphatase; p38 Mitogen-Activated Protein Kinases; Phosphoprotein Phosphatases; Phosphorylation; Pneumonia; PPAR gamma; Protein Kinase Inhibitors; Solubility; Tumor Necrosis Factor-alpha | 2010 |